Ninad A. Inamdar

Ninad A. Inamdar

Auto-generated profile, based on publicly available information

Ninad A. Inamdar

Department of Tumor Microenvironment and Metastasis, Moffitt Cancer Center and Research Institute, Tampa, Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in Cancer Research
Verified
Journal Article
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype. Significance: Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity.

16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Legends for Supplementary Figures and Supplementary Tables.

30 August 2019 in Indian Journal of Scientific Research
Verified
Journal Article
Open access
GRGeeta Rathnakumr
Geeta Rathnakumr
NINitin Inamdar
Nitin Inamdar
KGKinjalka Ghosh
Kinjalka Ghosh
International Journal of Science and Research (IJSR) Calls for Unique, Unpublished research papers in Engineering and Science

15 November 2022 in Blood
Verified
Journal Article
Open access
HSHarshini Sriram
Harshini Sriram
TKTwinkle Khanka
Twinkle Khanka
SGSanghamitra Gawai
Sanghamitra Gawai
SGSitaram Ghogale
Sitaram Ghogale
NDNilesh Deshpande
Nilesh Deshpande
PTPrashant R. Tembhare
Prashant R. Tembhare

16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype.Significance:Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity.

16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Validation of NOS-inhibition-mediated sensitization of NRAS-mutant melanoma cells to targeted MEK inhibition.